U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C31H44N2O5S
Molecular Weight 556.756
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DRONEDARONE

SMILES

CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C2=C(CCCC)OC3=CC=C(NS(C)(=O)=O)C=C23

InChI

InChIKey=ZQTNQVWKHCQYLQ-UHFFFAOYSA-N
InChI=1S/C31H44N2O5S/c1-5-8-12-29-30(27-23-25(32-39(4,35)36)15-18-28(27)38-29)31(34)24-13-16-26(17-14-24)37-22-11-21-33(19-9-6-2)20-10-7-3/h13-18,23,32H,5-12,19-22H2,1-4H3

HIDE SMILES / InChI

Molecular Formula C31H44N2O5S
Molecular Weight 556.756
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/ppa/dronedarone.html | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fa41601-7fb5-4155-8e50-2ae903f0d2d6 | http://www.rxlist.com/multaq-drug.htm

Dronedarone is an antiarrhythmic that is FDA approved for the treatment of atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF). Dronedarone is multichannel blocker. Common adverse reactions include abdominal pain, diarrhea, indigestion, nausea, vomiting, asthenia and raised serum creatinine. Dronedarone has potentially important pharmacodynamics interactions: Digoxin: Consider discontinuation or halve dose of digoxin before treatment and monitor; Calcium channel blockers (CCB): Initiate CCB with low dose and increase after ECG verification of tolerability; Beta-blockers: May provoke excessive bradycardia, Initiate with low dose and increase after ECG verification of tolerability.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MULTAQ

Approved Use

MULTAQ® is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF) [see Clinical Studies (14)

Launch Date

2009
Primary
MULTAQ

Approved Use

MULTAQ® is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF) [see Clinical Studies (14)

Launch Date

2009
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
96.2 ng/mL
1600 mg single, oral
dose: 1600 mg
route of administration: Oral
experiment type: SINGLE
co-administered: METOPROLOL
DRONEDARONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1386 ng × h/mL
1600 mg single, oral
dose: 1600 mg
route of administration: Oral
experiment type: SINGLE
co-administered: METOPROLOL
DRONEDARONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12 h
1600 mg single, oral
dose: 1600 mg
route of administration: Oral
experiment type: SINGLE
co-administered: METOPROLOL
DRONEDARONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 20-97 years
n = 3282
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: 20-97 years
Sex: M+F
Population Size: 3282
Sources:
Disc. AE: Gastrointestinal disorders, QT interval prolonged...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorders (3.2%)
QT interval prolonged (1.5%)
Sources:
1600 mg 2 times / day multiple, oral
Highest studied dose
Dose: 1600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1600 mg, 2 times / day
Sources:
healthy, 21-40 years
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Disc. AE: Diarrhea, Nausea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (6.7%)
Nausea (3.9%)
Abdominal pain upper (2%)
Abdominal pain (1.9%)
Vomiting (1.7%)
Dyspepsia (1.3%)
Nasopharyngitis (3.7%)
Upper respiratory tract infection (2.9%)
Dizziness (3.4%)
Blood creatinine increased (2.5%)
Hepatic enzyme increased (1.2%)
Blood urea increased (0.4%)
Bradycardia (2.6%)
Palpitations (1.1%)
Cardiac failure congestive (1.3%)
Cardiac failure (0.8%)
Fatigue (2.7%)
Oedema peripheral (4.2%)
Back pain (3.3%)
Arthralgia (3.1%)
Pain in extremity (2.1%)
Cough (2.2%)
Dyspnoea (2.3%)
Vertigo (1.3%)
Sources: Page: p. 103
400 mg 2 times / day steady, oral
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: NYHA Class IV heart failure | NYHA Class II - III heart failure
Age Group: adult
Sources:
Other AEs: Heart failure...
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 66
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 66
Sources: Page: p. 103
Disc. AE: Diarrhea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Diarrhea (7.6%)
Vomiting (1.5%)
Dyspepsia (3%)
Abdominal pain (1.5%)
Nasopharyngitis (4.5%)
Electrocardiogram QT prolonged (1.5%)
Blood creatinine increased (1.5%)
Hepatic enzyme increased (4.5%)
Blood urea increased (3%)
Bradycardia (1.5%)
Palpitations (6.1%)
Cardiac failure congestive (4.5%)
Cardiac failure (4.5%)
Fatigue (4.5%)
Cough (1.5%)
Hypokalemia (3%)
Vertigo (4.5%)
Sources: Page: p. 103
800 mg 2 times / day multiple, oral
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 62
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 62
Sources: Page: p. 103
Disc. AE: Diarrhea, Nausea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (29%)
Nausea (8.1%)
Vomiting (3.2%)
Abdominal pain (3.2%)
Influenza (3.2%)
Upper respiratory tract infection (1.6%)
Dizziness (4.8%)
Electrocardiogram QT prolonged (3.2%)
Hepatic enzyme increased (1.6%)
Blood urea increased (3.2%)
Bradycardia (6.5%)
Palpitations (4.8%)
Cardiac failure congestive (1.6%)
Cardiac failure (1.6%)
Fatigue (3.2%)
Atrial tachycardia (4.8%)
Cough (4.8%)
Vertigo (3.2%)
Sources: Page: p. 103
AEs

AEs

AESignificanceDosePopulation
QT interval prolonged 1.5%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 20-97 years
n = 3282
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: 20-97 years
Sex: M+F
Population Size: 3282
Sources:
Gastrointestinal disorders 3.2%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, 20-97 years
n = 3282
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: 20-97 years
Sex: M+F
Population Size: 3282
Sources:
Blood urea increased 0.4%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Cardiac failure 0.8%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Palpitations 1.1%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Hepatic enzyme increased 1.2%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Cardiac failure congestive 1.3%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Dyspepsia 1.3%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Vertigo 1.3%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Vomiting 1.7%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Abdominal pain 1.9%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Abdominal pain upper 2%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Pain in extremity 2.1%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Cough 2.2%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Dyspnoea 2.3%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Blood creatinine increased 2.5%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Bradycardia 2.6%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Fatigue 2.7%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Upper respiratory tract infection 2.9%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Arthralgia 3.1%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Back pain 3.3%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Dizziness 3.4%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Nasopharyngitis 3.7%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Nausea 3.9%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Oedema peripheral 4.2%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Diarrhea 6.7%
Disc. AE
400 mg 2 times / day steady, oral
Recommended
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 989
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 989
Sources: Page: p. 103
Heart failure grade 5
400 mg 2 times / day steady, oral
Dose: 400 mg, 2 times / day
Route: oral
Route: steady
Dose: 400 mg, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: NYHA Class IV heart failure | NYHA Class II - III heart failure
Age Group: adult
Sources:
Abdominal pain 1.5%
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 66
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 66
Sources: Page: p. 103
Blood creatinine increased 1.5%
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 66
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 66
Sources: Page: p. 103
Bradycardia 1.5%
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 66
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 66
Sources: Page: p. 103
Cough 1.5%
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 66
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 66
Sources: Page: p. 103
Electrocardiogram QT prolonged 1.5%
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 66
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 66
Sources: Page: p. 103
Vomiting 1.5%
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 66
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 66
Sources: Page: p. 103
Blood urea increased 3%
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 66
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 66
Sources: Page: p. 103
Dyspepsia 3%
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 66
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 66
Sources: Page: p. 103
Hypokalemia 3%
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 66
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 66
Sources: Page: p. 103
Cardiac failure congestive 4.5%
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 66
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 66
Sources: Page: p. 103
Cardiac failure 4.5%
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 66
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 66
Sources: Page: p. 103
Fatigue 4.5%
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 66
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 66
Sources: Page: p. 103
Hepatic enzyme increased 4.5%
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 66
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 66
Sources: Page: p. 103
Nasopharyngitis 4.5%
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 66
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 66
Sources: Page: p. 103
Vertigo 4.5%
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 66
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 66
Sources: Page: p. 103
Palpitations 6.1%
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 66
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 66
Sources: Page: p. 103
Diarrhea 7.6%
Disc. AE
600 mg 2 times / day multiple, oral
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 66
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 66
Sources: Page: p. 103
Cardiac failure congestive 1.6%
Disc. AE
800 mg 2 times / day multiple, oral
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 62
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 62
Sources: Page: p. 103
Cardiac failure 1.6%
Disc. AE
800 mg 2 times / day multiple, oral
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 62
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 62
Sources: Page: p. 103
Hepatic enzyme increased 1.6%
Disc. AE
800 mg 2 times / day multiple, oral
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 62
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 62
Sources: Page: p. 103
Upper respiratory tract infection 1.6%
Disc. AE
800 mg 2 times / day multiple, oral
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 62
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 62
Sources: Page: p. 103
Diarrhea 29%
Disc. AE
800 mg 2 times / day multiple, oral
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 62
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 62
Sources: Page: p. 103
Abdominal pain 3.2%
Disc. AE
800 mg 2 times / day multiple, oral
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 62
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 62
Sources: Page: p. 103
Blood urea increased 3.2%
Disc. AE
800 mg 2 times / day multiple, oral
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 62
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 62
Sources: Page: p. 103
Electrocardiogram QT prolonged 3.2%
Disc. AE
800 mg 2 times / day multiple, oral
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 62
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 62
Sources: Page: p. 103
Fatigue 3.2%
Disc. AE
800 mg 2 times / day multiple, oral
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 62
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 62
Sources: Page: p. 103
Influenza 3.2%
Disc. AE
800 mg 2 times / day multiple, oral
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 62
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 62
Sources: Page: p. 103
Vertigo 3.2%
Disc. AE
800 mg 2 times / day multiple, oral
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 62
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 62
Sources: Page: p. 103
Vomiting 3.2%
Disc. AE
800 mg 2 times / day multiple, oral
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 62
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 62
Sources: Page: p. 103
Atrial tachycardia 4.8%
Disc. AE
800 mg 2 times / day multiple, oral
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 62
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 62
Sources: Page: p. 103
Cough 4.8%
Disc. AE
800 mg 2 times / day multiple, oral
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 62
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 62
Sources: Page: p. 103
Dizziness 4.8%
Disc. AE
800 mg 2 times / day multiple, oral
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 62
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 62
Sources: Page: p. 103
Palpitations 4.8%
Disc. AE
800 mg 2 times / day multiple, oral
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 62
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 62
Sources: Page: p. 103
Bradycardia 6.5%
Disc. AE
800 mg 2 times / day multiple, oral
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 62
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 62
Sources: Page: p. 103
Nausea 8.1%
Disc. AE
800 mg 2 times / day multiple, oral
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Sources: Page: p. 103
unhealthy, adult
n = 62
Health Status: unhealthy
Condition: atrial fibrillation | atrial flutter
Age Group: adult
Sex: M+F
Population Size: 62
Sources: Page: p. 103
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
likely
moderate [Ki 8.12 uM]
yes (co-administration study)
Comment: dronedarone increased verapamil exposure by 1.4- fold, and nisoldipine exposure by 1.5- fold; dronedarone increased simvastatin, a sensitive CYP3A substrate, and simvastatin acid exposure by 4- fold and 2- fold, respectively;
Page: 76,89,194
no
no
no
no
no
no
not significant
not significant
not significant
not significant
not significant
not significant
not significant
weak (co-administration study)
Comment: dronedarone increased S-warfarin exposure by 1.2- fold
Page: 76.0
strong [IC50 0.97 uM]
yes (co-administration study)
Comment: IC50 value obtained using vincristine as substrate; increased S-warfarin exposure by 1.2- fold
Page: 76,90
weak [Ki 4.37 uM]
yes (co-administration study)
Comment: dronedarone increased metoprolol exposure by 1.6- and 2.3- fold, respectively; increased propranolol exposure by 1.3- fold;
Page: 76,89,194
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: administration of ketoconazole resulted in a 17- to 25- fold increase in dronedarone exposure; administration with rifampicin decreased dronedarone exposure by 80%
Page: 76,89
no
no
unlikely
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction.
2000 Sep
Mechanisms of action of antiarrhythmic drugs relative to the origin and perpetuation of cardiac arrhythmias.
2001 Jan
Newer antiarrhythmic drugs.
2001 May-Jun
Beneficial effects of amiodarone and dronedarone (SR 33589b), when applied during low-flow ischemia, on arrhythmia and functional parameters asssessed during reperfusion in isolated rat hearts.
2001 Oct
Recent advances in arrhythmia therapy: treatment and prevention of atrial fibrillation.
2002 Apr
The JT-area indicates dispersion of repolarization in dogs with atrioventricular block.
2002 Jun
Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone.
2002 May
Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and postischemic performance of the isolated rat heart.
2002 May 31
Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes.
2003 Aug
Electrophysiologic characterization of dronedarone in guinea pig ventricular cells.
2003 Feb
Dronerarone acts as a selective inhibitor of 3,5,3'-triiodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence.
2003 Feb
Chronic amiodarone-induced inhibition of the Na+-K+ pump in rabbit cardiac myocytes is thyroid-dependent: comparison with dronedarone.
2003 Jan
Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
2003 Mar 20
Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels.
2003 Nov
Dronedarone: an amiodarone analogue.
2004 Apr
High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656.
2004 Dec 17
A benefit-risk assessment of class III antiarrhythmic agents.
2004 Nov
Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
2005
[Safety of new anti-arrhythmic drugs].
2005 Apr
In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias.
2005 Feb
This DAFNE is definitely not that DAFNE.
2005 May 25
Comment on dronedarone.
2006 Dec
Dronedarone: a new antiarrhythmic agent.
2006 Feb
Amiodarone inhibits thyroidal iodide transport in vitro by a cyclic adenosine 5'-monophosphate- and iodine-independent mechanism.
2006 Jun
Drug evaluation: dronedarone, a novel non-iodinated anti-arrhythmic agent.
2006 Sep
Dronedarone: drondarone, SR 33589, SR 33589B.
2007
Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin.
2007 Aug 1
Dronedarone in atrial fibrillation.
2007 Dec 6
Pharmacological inhibition of TRalpha1 receptor potentiates the thyroxine effect on body weight reduction in rats: potential therapeutic implications in controlling body weight.
2007 Jan
Effect of amiodarone and dronedarone administration in rats on thyroid hormone-dependent gene expression in different cardiac components.
2007 Jun
Comparative antiarrhythmic efficacy of amiodarone and dronedarone during acute myocardial infarction in rats.
2007 Jun 14
A review of the investigational antiarrhythmic agent dronedarone.
2007 Mar
Acute in vitro effects of dronedarone, an iodine-free derivative, and amiodarone, on the rabbit sinoatrial node automaticity: a comparative study.
2007 Sep
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
2007 Sep 6
[Efficacy of dronedarone in cardiac failure due to severe left ventricular systolic dysfunction. Results of the ANDROMEDA].
2008
Atrial fibrillation after cardiac surgery: where are we now?
2008
Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.
2008
Acute inhibitory effect of dronedarone, a noniodinated benzofuran analogue of amiodarone, on Na+/Ca2+ exchange current in guinea pig cardiac ventricular myocytes.
2008 Jun
Update on atrial fibrillation: part II.
2008 Mar
Is dronedarone effective for the prevention of recurrent atrial fibrillation?
2008 Mar
Dronedarone: a new treatment for atrial fibrillation.
2008 Nov
Amiodarone as paradigm for developing new drugs for atrial fibrillation.
2008 Oct
Alternatives to amiodarone: search for the Holy Grail.
2009 Apr
A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology.
2009 Apr
Dronedarone for atrial fibrillation--an odyssey.
2009 Apr 30
Clinical trials update from the Heart Failure Society of America and the American Heart Association meetings in 2008: SADHART-CHF, COMPARE, MOMENTUM, thyroid hormone analogue study, HF-ACTION, I-PRESERVE, beta-interferon study, BACH, and ATHENA.
2009 Feb
Effect of dronedarone on cardiovascular events in atrial fibrillation.
2009 Feb 12
Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?
2009 Jan
Benzofuran derivatives and the thyroid.
2009 Jan
The role of thyroid hormone nuclear receptors in the heart: evidence from pharmacological approaches.
2010 Mar
Patents

Sample Use Guides

One tablet of 400 mg twice a day with morning and evening meals.
Route of Administration: Oral
In isolated ventricular myocytes, dronedarone inhibited rapidly activating delayed-rectifier K+ current (I(Kr)) (median inhibitory concentration [IC50] /= 30 uM).
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:18:50 GMT 2023
Edited
by admin
on Fri Dec 15 16:18:50 GMT 2023
Record UNII
JQZ1L091Y2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DRONEDARONE
EMA EPAR   INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
dronedarone [INN]
Common Name English
METHANESULFONAMIDE, N-(2-BUTYL-3-(4-(3-(DIBUTYLAMINO)PROPOXY)BENZOYL)-5-BENZOFURANYL)-
Systematic Name English
SR33589
Code English
SR-33589
Code English
DRONEDARONE [VANDF]
Common Name English
N-(2-BUTYL-3-(4-(3-(DIBUTYLAMINO)PROPROXY)BENZOYL)BENZOFURAN-5-YL)METHANESULFONAMIDE
Common Name English
DRONEDARONE [EMA EPAR]
Common Name English
Dronedarone [WHO-DD]
Common Name English
DRONEDARONE [MI]
Common Name English
DRONEDARONE [MART.]
Common Name English
Classification Tree Code System Code
WHO-VATC QC01BD07
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
LIVERTOX NBK548208
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
NDF-RT N0000175426
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
WHO-ATC C01BD07
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
NCI_THESAURUS C47793
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
Code System Code Type Description
WIKIPEDIA
DRONEDARONE
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY
DRUG BANK
DB04855
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY
NDF-RT
N0000185503
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY P-Glycoprotein Inhibitors [MoA]
RXCUI
233698
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY RxNorm
SMS_ID
100000081006
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY
PUBCHEM
208898
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY
MESH
C118667
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY
EPA CompTox
DTXSID3048653
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY
HSDB
7928
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY
MERCK INDEX
m4768
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY Merck Index
NDF-RT
N0000182137
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY Cytochrome P450 2D6 Inhibitors [MoA]
IUPHAR
7465
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY
CAS
141626-36-0
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY
EVMPD
SUB06408MIG
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY
DAILYMED
JQZ1L091Y2
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY
ChEMBL
CHEMBL184412
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY
NDF-RT
N0000190114
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY Cytochrome P450 3A Inhibitors [MoA]
CHEBI
50659
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY
NCI_THESAURUS
C65485
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY
INN
7382
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY
FDA UNII
JQZ1L091Y2
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY
DRUG CENTRAL
4112
Created by admin on Fri Dec 15 16:18:50 GMT 2023 , Edited by admin on Fri Dec 15 16:18:50 GMT 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
MINOR
EXCRETED UNCHANGED
Mass balance indicates that orally administered dronedarone is ultimately excreted in the urine (6 %) and feces (84 %) primarily as metabolites. Dronedarone was extensively metabolized; only low amounts of dronedarone were detected in feces and dronedarone was non-existent in urine.
AMOUNT EXCRETED
URINE
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> INHIBITOR
LOW
Ki
METABOLIC ENZYME -> INHIBITOR
LOW
Ki
METABOLIC ENZYME -> SUBSTRATE
MAJOR
TRANSPORTER -> INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
FECAL; URINE
METABOLITE -> PARENT
MAJOR
PLASMA
METABOLITE -> PARENT
FECAL; URINE
METABOLITE -> PARENT
METABOLITE -> PARENT
FECAL; URINE
METABOLITE LESS ACTIVE -> PARENT
Dronedarone is extensively metabolized, mainly by CYP 3A
MAJOR
PLASMA
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC IN HEPATICALLY IMPAIRED PATIENTS

DOSE

Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC IN HEALTHY SUBJECTS

DOSE